All articles tagged: Atopic neurodermatitis (L20.81)

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) cream, 0.15 percent, for the treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients (ages 6 years and older).Zoryve is a once-daily, steroid-free cream that the company says will be available at the end of July.The approval was based on resu

Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according to a study presented at the annual Revolutionizing Atopic Dermatitis Conference, held from June 8 to 10 in Chicago.Jonathan I. Silverberg, M.D., Ph.D., M.P.H., from the George Washington Unive

Climatic hazards are likely to aggravate atopic dermatitis (AD), with the impact including direct and indirect effects, according to a review published online Jan. 24 in Allergy.Sheng-Pei Wang, M.D., M.P.H., from the University of California San Francisco, and colleagues identified 18 studies with evidence for an impact of AD by leve

An increase in carbon monoxide (CO) levels associated with the Canadian wildfires of 2023 correlated with increased atopic dermatitis (AD), dermatitis, and eczema-related clinic visits in a Boston hospital system, according to a study published online Dec. 16 in Dermatology and Therapy.Kathyana P. Santiago Mangual, from Massachusetts

In updated guidelines issued by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology, and published online Dec. 17 in the Annals of Allergy, Asthma & Immunology, recommendations are presented for gaining and maintaining control of atopic dermatitis (AD).Derek K. Chu, M.D., Ph.D.

In updated guidelines issued by the American Academy of Dermatology and published online Nov. 7 in the Journal of the American Academy of Dermatology, recommendations are presented for use of phototherapy and systemic therapies for atopic dermatitis (AD) and include strong endorsements of monoclonal antibodies and Janus kinase inhib

Skin diseases can cause a psychosocial burden and feelings of stigmatization, according to a study published online Oct. 8 in the Journal of the European Academy of Dermatology and Venereology.Paolo Gisondi, M.D., from the University of Verona in Italy, and colleagues evaluated the burden of the most common dermatological diseases

For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in JAMA Dermatology.Celeste M. Boesjes, M.D., from the University Medical Center Utrecht in the Netherlands, and colleag

Adolescents with atopic dermatitis have higher odds of being bullied at higher frequency after adjustment for demographics, atopic comorbidities